S&P 500   4,590.43 (+1.15%)
DOW   35,246.95 (+1.93%)
QQQ   383.58 (+0.12%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
S&P 500   4,590.43 (+1.15%)
DOW   35,246.95 (+1.93%)
QQQ   383.58 (+0.12%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
S&P 500   4,590.43 (+1.15%)
DOW   35,246.95 (+1.93%)
QQQ   383.58 (+0.12%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
S&P 500   4,590.43 (+1.15%)
DOW   35,246.95 (+1.93%)
QQQ   383.58 (+0.12%)
AAPL   165.88 (+2.50%)
MSFT   322.19 (-0.25%)
FB   314.61 (+2.53%)
GOOGL   2,841.58 (+0.05%)
AMZN   3,433.77 (+1.30%)
TSLA   981.02 (-3.34%)
NVDA   291.05 (-5.17%)
BABA   120.51 (+7.64%)
NIO   31.89 (-0.81%)
CGC   9.92 (-0.70%)
AMD   135.22 (-6.10%)
GE   96.57 (+4.10%)
MU   81.88 (+0.32%)
T   23.51 (+0.21%)
F   19.25 (+0.57%)
DIS   150.07 (+2.63%)
PFE   52.18 (-3.85%)
AMC   28.38 (-2.17%)
ACB   5.84 (+0.34%)
BA   206.00 (+3.78%)
NASDAQ:BMRA

Biomerica Stock Forecast, Price & News

$4.30
-0.01 (-0.23%)
(As of 12/6/2021 10:52 AM ET)
Add
Compare
Today's Range
$4.21
$4.30
50-Day Range
$4.12
$6.71
52-Week Range
$3.30
$8.15
Volume
152 shs
Average Volume
793,758 shs
Market Capitalization
$53.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.63
30 days | 90 days | 365 days | Advanced Chart
Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.


Biomerica logo

About Biomerica

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Headlines

Biomerica, Inc. (NASDAQ:BMRA) Short Interest Down 18.9% in October
November 21, 2021 |  americanbankingnews.com
Biomerica Vaults on Patent News - Baystreet.ca
November 8, 2021 |  baystreet.ca
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMRA
Employees
45
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.20 million
Book Value
$0.75 per share

Profitability

Net Income
$-7.45 million
Pretax Margin
-96.69%

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,546,000
Market Cap
$53.80 million
Optionable
Not Optionable

Company Calendar

Last Earnings
10/15/2021
Today
12/06/2021
Next Earnings (Estimated)
1/13/2022
Fiscal Year End
5/31/2022

MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

706th out of 1,390 stocks

Diagnostic Substances Industry

8th out of 25 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Biomerica (NASDAQ:BMRA) Frequently Asked Questions

Is Biomerica a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biomerica stock.
View analyst ratings for Biomerica
or view top-rated stocks.

How has Biomerica's stock been impacted by Coronavirus?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BMRA stock has increased by 48.3% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Biomerica?

Biomerica saw a decline in short interest in the month of October. As of October 29th, there was short interest totaling 1,070,000 shares, a decline of 18.9% from the October 14th total of 1,320,000 shares. Based on an average trading volume of 2,030,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 10.3% of the shares of the stock are sold short.
View Biomerica's Short Interest
.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Thursday, January 13th 2022.
View our earnings forecast for Biomerica
.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) issued its quarterly earnings results on Friday, October, 15th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The firm had revenue of $1.26 million for the quarter. Biomerica had a negative trailing twelve-month return on equity of 64.01% and a negative net margin of 86.94%.
View Biomerica's earnings history
.

What price target have analysts set for BMRA?

2 analysts have issued 12-month target prices for Biomerica's shares. Their forecasts range from $10.00 to $13.00. On average, they expect Biomerica's share price to reach $11.50 in the next year. This suggests a possible upside of 167.4% from the stock's current price.
View analysts' price targets for Biomerica
or view top-rated stocks among Wall Street analysts.

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Zackary S. Irani, Chairman & Chief Executive Officer
  • Steve Sloan, Chief Financial Officer & Treasurer
  • Allen C. Barbieri, Executive Vice Chairman & Secretary

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by many different retail and institutional investors. Top institutional investors include Granahan Investment Management Inc. MA (8.24%), BlackRock Inc. (1.37%), GWM Advisors LLC (0.25%), Eudaimonia Partners LLC (0.09%), HCR Wealth Advisors (0.08%) and Belvedere Trading LLC (0.00%). Company insiders that own Biomerica stock include Catherine Coste and Mark A Sirgo.
View institutional ownership trends for Biomerica
.

Which institutional investors are selling Biomerica stock?

BMRA stock was sold by a variety of institutional investors in the last quarter, including GWM Advisors LLC.
View insider buying and selling activity for Biomerica
or view top insider-selling stocks.

Which institutional investors are buying Biomerica stock?

BMRA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eudaimonia Partners LLC, HCR Wealth Advisors, Granahan Investment Management Inc. MA, and Belvedere Trading LLC.
View insider buying and selling activity for Biomerica
or or view top insider-buying stocks.

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $4.30.

How much money does Biomerica make?

Biomerica has a market capitalization of $53.80 million and generates $7.20 million in revenue each year. The company earns $-7.45 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Biomerica have?

Biomerica employs 45 workers across the globe.

What is Biomerica's official website?

The official website for Biomerica is www.biomerica.com.

Where are Biomerica's headquarters?

Biomerica is headquartered at 17571 Von Karman Avenue, Irvine CA, 92614.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at (949) 645-2111 or via fax at 949-553-1231.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.